November 16, 2021
Life Sciences
  • Pfizer has agreed to a licensing deal with the U.N.’s Medicines Patent Pool for its COVID-19 pill. Under the agreement, Pfizer will manufacture and supply its effective antiviral pill in 95 countries, including all low-income and lower-middle-income nations. The company will not receive royalties for sales in the low-income countries, and it will waive royalties for sales in all the other countries that are under the agreement for as long as the World Health Organization labels COVID-19 a Public Emergency of International Concern. (Article here)